Abstract:
The present invention relates to novel 5,6-dihydropyrone derivatives and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The 5,6-dihydropyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized 5,6-dihydropyrones and of related structures.
Abstract:
삼중결합을 2개 이상 갖는 설파이드 화합물을 머캅토기를 갖는 알콜 화합물과 반응시켜 황을 함유하는 4관능 이상의 폴리올 화합물을 제조한 뒤, 티오우레아와 반응 및 가수분해시켜 얻은 일 실시예의 폴리티올 화합물은, 이소시아네이트 화합물과의 반응을 통해, 굴절률 및 아베수와 같은 광학특성 뿐만 아니라 내열성과 내충격성도 우수한 폴리티오우레탄계 화합물을 제공할 수 있어, 안경 렌즈, 카메라 렌즈 등의 광학재료의 제조에 유용하게 사용될 수 있다. 다른 실시예의 제조방법에 따르면, 반응 시간을 단축시키면서 수율과 순도가 향상된 무색투명한 폴리올을 제조할 수 있고, 상기 폴리올을 이용하여 황색도가 낮고 선명한 광학용 렌즈를 제조할 수 있다.
Abstract:
Novel imidazolium [1,2a] pyridine (ImPr) based protic ionic liquids with thiolate/disulfide and different carboxylate anions have been synthesized and characterized by NMR, IR and Mass spectroscopy. Thermogravimetry analysis (TGA) has been done to investigate the thermal behavior of these protic ionic liquids. Their decomposition temperatures are determined in the range of 126-175°C except [ImPr][HSO4] which is most stable with decomposition temperature of 326°C. Differential Scanning Calorimetry (DSC) has been used to analyze phase behavior of these protic Ionic liquid. Glass transition temperature has been observed for all the synthesized PILs. Ionic conductivity of [Impr] [Pim] is measured at 25 °C, 58.6 µS/cm, which is a relatively good conductivity in comparison with imidazolium-based ionic liquids. All ionic liquids were synthesized using an environmentally friendly solvent free method.
Abstract:
The present invention describes chemical systems and methods for reducing C-O, C-N, and C-S bonds, said system comprising a mixture of (a) at least one organosilane and (b) at least one strong base, said system being substantially free of a transition-metal compound, and said system optionally comprising at least one molecular hydrogen donor compound, molecular hydrogen, or both.
Abstract:
The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula (I), as defined in the specification. The invention also relates to methods of using compounds of Formula (I), or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.
Abstract:
Provided is a process for preparing thiophenol derivatives, using aromatic disulfide as a starting material, and inexpensive sodium bisulfite (NaHSO 3 ) as a reducing agent. The process can be carried out on an industrial scale at low production costs, secures advantageous reaction conditions by using a small amount of water- soluble alcohol solvent. Further, the process can maximize the purity of the products by inhibiting reverse oxidation of the final product by the action of sulfur dioxide (SO 2 ) produced during the preparation process, after solvent extraction of the starting materials present as impurities of the thiophenol derivatives.
Abstract translation:提供了使用芳族二硫化物作为原料制备苯硫酚衍生物和廉价的亚硫酸氢钠(NaHSO 3)作为还原剂的方法。 该方法可以以低生产成本在工业规模下进行,通过使用少量的水溶性醇溶剂确保有利的反应条件。 此外,该方法可以通过在制备过程中产生的二氧化硫(SO 2 O 2)的作用下,在溶剂萃取原料存在后,通过抑制最终产物的反向氧化来最大化产物的纯度 作为苯硫酚衍生物的杂质。
Abstract:
The invention relates to a particularly advantageous method for producing aryl thiols through the catalytic hydrogenation of diaryldisulphides. According to the invention, the hydrogenation is carried out in a basic alcoholic medium.